Incyte Corporation announced executive leadership title changes effective March 25, 2026. Pablo J. Cagnoni is now President, Incyte and Global Head of Research and Development, replacing William J.

Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026.

Exelixis, Inc. filed an 8-K on March 10, 2026, announcing its financial results for the fourth quarter and full year ended December 31, 2025. The press release, furnished as Exhibit 99.

Ionis Pharmaceuticals announced significant changes to its Board of Directors. B. Lynne Parshall and Joseph H. Wender will retire at the end of their terms in June 2026.